Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

16 recalls · Class II, newest first

Class II · Moderate risk

Betaxolol Ophthalmic Solution

Microbial Contamination of Sterile Products: Confirmed sterility failure identified during stability testing at the 12-month time point.

Terminated Microbial contamination Akorn, Inc. NDC 17478-705-11 D-0004-2022
Class II · Moderate risk

Valproic Acid Oral Solution

CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms.

Terminated Microbial contamination American Health Packaging D-0854-2021
Class II · Moderate risk

Valproic Acid Oral Solution USP

CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms.

Completed Microbial contamination Morton Grove Pharmaceuticals, Inc. D-0816-2021
Class II · Moderate risk

Promethazine Syrup Plain

CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms.

Completed Microbial contamination Morton Grove Pharmaceuticals, Inc. D-0814-2021
Class II · Moderate risk

Rompe Pecho DM

Microbial Contamination of Non-Sterile Products

Terminated Microbial contamination Efficient Laboratories, Inc. NDC 58593-275-06 D-0291-2022
Class II · Moderate risk

Artificial Tears Ointment

Non-Sterility - OOS sterility testing observed during 12-month controlled room temperature stability testing. The microbiological investigation identified the organism as a member of the Bacillus cereus group.

Terminated Microbial contamination Akorn, Inc. NDC 17478-062-35 D-0786-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 57237-266-01 D-0776-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 70199-014-01 D-0775-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 0591-3330-01 D-0774-2021

Recalls by year